Pluvicto therapy is a novel treatment that offers fresh hope to certain individuals with advanced prostate cancer. After a much-anticipated launch last year, the manufacturer temporarily paused production. Now production has resumed, and the leading-edge treatment is once again offered at Lehigh Valley Topper Cancer Institute.
Candidates for Pluvicto have metastatic castrate-resistant prostate cancer (mCRPC) that is prostate-specific membrane antigen-positive (PSMA+). Their cancer is progressive even after prior treatment with other anti-cancer therapies, including an androgen-receptor pathway inhibitor and a taxane-based chemotherapy regimen.
“There is a significant unmet need for more treatment options in this group of patients,” says Paul Palyca, MD, a hematologist oncologist with the Cancer Institute. “About 10 to 20 percent of individuals with existing metastatic prostate cancer will reach the castrate-resistant state within three years, and this state remains lethal despite all the advancements we’ve made over the past decade.”